Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221838 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
A Phase 4 study, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT07221838: Recruiting Phase 4 study, sponsored by Alexion Pharmaceuticals.
NCT07221838 is a Phase 4 study that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 75 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221838, a Phase 4 study, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
Interventions
- DRUG Ravulizumab
- DRUG Prednisone/Prednisolone
- PROCEDURE Oral Corticosteroid Tapering Schedule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2027-08-27 |
| Phase | Phase 4 |
What NCT07221838 shows while recruiting
NCT07221838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Ravulizumab is the first listed.
NCT07221838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07221838 about?
NCT07221838 is a clinical study titled "A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab". This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated wi...
What is the current status of trial NCT07221838?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2026-03-04. Estimated completion is 2027-08-27.
What interventions are being tested in trial NCT07221838?
The interventions under investigation include: Ravulizumab (DRUG), Prednisone/Prednisolone (DRUG), Oral Corticosteroid Tapering Schedule (PROCEDURE).
Who is sponsoring clinical trial NCT07221838?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07221838's enrollment target sits among peer trials
75 1002nd of 2000 higher than 974 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI